A complete global analysis of the
prospects for markets and companies in this dynamic industry sector
Features and benefits of this
thoroughly-researched and highly-regarded management report:
- High quality research and forecasts: Independent research, combined with detailed 5-year forecasts, informed commentary and unrivalled primary source data will aid your business planning and decision-making process
- Global coverage - with 74 country markets profiles: Scope opportunities for new investment or sales growth, with detailed historical data and forecasts on the leading developed economies as well as key emerging markets from Africa, the Americas, Asia, Emerging Europe, and the Middle East
- Issue driven: Understand the latest company, product, and regulatory developments
- Company Insight - with the 26 leading companies reviewed: Who’s working with whom? Who’s suing whom? Who’s up, who’s down? Assess the activities, strategies and market position of your competitors, partners and clients
- Flexible formats: Available in pdf format with online access included in the price. Cost-effective distribution licences can ensure you get the best from your investment
- Biosimilars: Coverage of the fast developing biosimilars market
- Easily understand the threats and opportunities that are shaping this rapidly evolving sector!
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/world-generic-market-report-2013
Industry Issues
If the branded pharmaceutical
industry was facing a patent cliff it is now teetering on the edge of it.
Ironically, it is the world’s best selling drug, Lipitor, which exemplifies the
trend. Despite still having patent protection, Pfizer has been unable to stem
the tide of interest and pressure from a number of companies, Ranbaxy being
chief amongst them. Despite pressure on prices in many markets, the generic
sector continues to thrive with increased sales across the board in 2012. The
maturity of the sector can also be seen in the size of the businesses: there
are now 18 generic companies with revenues in excess of US$1,000 million, 6
more than in 2008/09..
Company Assessments
In recent years there has been a
trend towards consolidation, both within the generics industry itself, and
between the generics industry and the branded industry. This has been a trend
born of necessity, reflecting both the difficult economic environment and the
slowdown in development of innovative drugs. Without doubt, the most important
and largest acquisition to have taken place over the last year has been the
merger between Watson Pharmaceuticals and Actavis. The merger has created a
company with revenues for the year ended 31st December 2012 of just over US$5.9
billion.
Market Analysis
The generic market is experiencing
two opposing trends driven by the global downturn. On one hand, the use of
generics is increasing due to their cost-effectiveness and adoption has
accelerated in markets where branded prescribing was dominant. On the other
hand, the squeeze on government spending has not left generics untouched, with
many countries lowering generic prices through cuts in reimbursement rates or
contract tendering with a resultant squeeze on margins.
Industry consolidation, new market
opportunities, the latest on biosimilars plus much, much more!
This leading report, now in its 11th
year of publication, draws on primary research with companies, statistics
offices, health ministries and trade associations worldwide and provides
standard, comparative data and discussion on key issues. This extensive data
set is interpreted and evaluated by the editors to provide a complete and
compelling review of the whole sector.
To Buy The Copy of
This Report Visit: http://www.marketresearchreports.biz/analysis/170302
About Us
MarketResearchReports.Biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are especially designed to save time and
money of our clients. We are a one stop solution for all your research needs,
our main offerings are syndicated research reports, custom research,
subscription access and consulting services. We serve all sizes and types of
companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment